Navidea Biopharmaceuticals (NYSE:NAVB) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB) in a report released on Monday. The firm issued a sell rating on the stock.

Navidea Biopharmaceuticals Price Performance

Shares of NAVB stock opened at $0.04 on Monday. The firm has a market capitalization of $3.81 million, a P/E ratio of -0.64 and a beta of 1.13. Navidea Biopharmaceuticals has a twelve month low of $0.02 and a twelve month high of $0.27. The stock’s fifty day simple moving average is $0.04 and its 200 day simple moving average is $0.05.

Navidea Biopharmaceuticals Company Profile

Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases.